SEC Form 4 · accession 0001601830-26-000082
RECURSION PHARMACEUTICALS, INC. · RXRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Namandje Bumpus
Director
Period of report
Jun 17, 2026
Accepted (ET)
Jun 22, 2026 · 4:32 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001601830
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | Jun 17, 2026 | A | 88,424 | $0.00 | A | 131,595 | D | |
| Class A Common Stock | Jun 18, 2026 | S | 3,963 | $3.18 | D | 127,632 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 17,2027 or the day prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.
- F2This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026.